A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy


Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M. L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., Rohrbach, R., Chang, C. C., McDaniel, L., Flores, I., Gaiser, R., Edinger, M., Wolff, D., Heidenreich, M., Strati, P., Nair, R., Chihara, D., Fayad, L. E., Ahmed, S., Iyer, S. P., Steiner, R. E., Jain, P., Nastoupil, L. J., Westin, J., Arora, R., Wang, M. L., Turner, J., Menges, M., Hidalgo-Vargas, M., Reid, K., Dreger, P., Schmitt, A., Müller-Tidow, C., Locke, F. L., Davila, M. L., Champlin, R. E., Flowers, C. R., Shpall, E. J., Poeck, H., Neelapu, S. S., Schmitt, M., Subklewe, M., Jain, M. D., Jenq, R. R. & Elinav, E. (2023). Nat Med.

DOI:10.1038/s41591-023-02234-6